The present study aimed to investigate the effects of tamoxifen (TMX) on locomotor behavior and on the activities of mitochondrial respiratory chain complexes and creatine kinase (CK) in the brain of rats subjected to an animal model of mania induced by D-amphetamine (D-AMPH)-reversion and prevention protocols. The D-AMPH administration increased locomotor activity in saline-treated rats under prevention and reversion treatment; furthermore, there was evident reduction in the locomotion in the D-amphetamine group treated with TMX. D-AMPH significantly decreased the activity of mitochondrial respiratory chain complexes in saline-treated rats in prefrontal cortex, hippocampus, striatum and amygdala in both prevention and reversion treatment. Depending on the cerebral area and evaluated complex, TMX was able to prevent and reverse this impairment. A decrease in CK activity was also verified in the brain of rats when D-AMPH was administrated in both experiments; the administration of TMX reversed but not prevented the decrease in CK activity induced by D-AMPH. The present study demonstrated that TMX reversed and prevented the alterations in behavioral and energy metabolism induced by D-AMPH (alterations were also observed in bipolar disorder), reinforcing the need for more studies about inhibitors of PKC as possible targets for new medications in the treatment of bipolar disorder.
Introduction
Bipolar disorder (BD) is a common and severe mood disorder that causes recurrent mood switches including manic, depressive, and mixed episodes (Manning et al., 1997) . This condition is associated to emotionally damaging behaviour and bears a 15% risk of suicide when left untreated (McIntyre et al., 2008) .
The mania, considered the clinical hallmark of the disease, shows symptoms such as euphoria, excessive energy, grandiosity, acceleration, intense sensation of pleasure or a highly irritable and aggressive state (Calabrese et al., 2003) . The treatment of acute mania with lithium, valproate, carbamazepine and atypical antipsychotics has shown great progress, however many patients do not tolerate or respond adequately to these drugs (Evins et al., 2006) . In addition, these treatments necessitate continuous long-term use and are thus non-curative (Ludtmann et al., 2011) , requiring new approaches in BD pharmacotherapy.
Evidences from literature strongly suggest a dysregulation of mitochondrial function and energetic metabolism in the pathophysiology of neuropsychiatric disorders, including BD (Kato and Kato, 2000; Konradi et al., 2004; Quiroz et al., 2008) . In this context, in vivo magnetic resonance spectroscopy studies have demonstrated changes in brain compounds related to energy production, oxidative phosphorylation and phospholipid metabolism in bipolar patients (Stork and Renshaw, 2005) . Moreover, neuroimaging studies (Cecil et al., 2002; Bertolino et al., 2003; Deicken et al., 2003) , postmortem brain (Konradi et al., 2004; Vawter et al., 2006) , and animal models (Corrêa et al., 2007; Valvassori et al., 2010) suggest that the decrease in mitochondrial function with consequent impairment of cell energy production is a hypothesis which might explain the pathophysiology of BD. These observations suggest that enhancing mitochondrial Pharmacology, Biochemistry and Behavior 98 (2011) 
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Pharmacology, Biochemistry and Behavior j o u r n a l h o m e p a g e : w w w. e l s ev i e r. c o m / l o c a t e / p h a r m b i o c h e m b e h function may represent an important strategy for the optimal longterm treatment of BD (Quiroz et al., 2008) . Creatine kinase (CK) is an enzyme that plays a central role in cells with high and fluctuating energy requirements, including neurons (Andres et al., 2008) , where it acts as an effective buffering system of cellular ATP levels. A study by MacDonald et al. (2006) showed that the expression levels of mRNA transcripts coding for brain creatine kinase and mitochondrial 1 ubiquitous are downregulated in the hippocampus and dorsolateral prefrontal cortex in the postmortem brain of bipolar patients. Additionally, in an animal model of mania, was demonstrated that the levels of CK are decreased in brain tissue (Streck et al., 2008) .
Several lines of evidence also implicate abnormal protein kinase C (PKC) activity in BD. This protein is mainly found in the brain, where it exerts fundamental role in pre and post-synaptic neurotransmission, regulating neuronal excitability, neurotransmitter release and cellular plasticity (Manji and Lenox, 1999) . Psychostimulant drugs seem to activate PKC (Einat et al., 2007; Boudanova et al., 2008) and evidences suggest that lithium and valproate attenuate the function of this protein, indicating that PKC modulation plays a key role in the treatment of mania (Chen et al., 2000; Kirshenboim et al., 2004; Hahn et al., 2005) . Recent preclinical and clinical studies have demonstrated that tamoxifen (TMX-an inhibitor of PKC) significantly reduces hyperactivity and risky behavior caused by D-AMPH administration in animals and also reduces manic symptoms in patients (Bebchuk et al., 2000; Einat et al., 2007; Zarate et al., 2007; Yildiz et al., 2008) , suggesting efficacy of TMX in the treatment of mania. In addition, Tuquet et al. (2000) demonstrated that TMX interacts with mitochondrial respiratory chain in the isolated mitochondria from rat liver, suggesting a correlation between PKC inhibition and increased energy metabolism.
The fluctuating pattern of BD hampers the development of a suitable animal model that includes all the symptoms of the disorder. The clinical hallmark for the diagnosis of BD is the presence of manic symptoms (Belmaker, 2004) so the usual animal models for BD are focused on the expression of a single manic episode. The psychostimulant-induced hyperactivity is the best established animal model of mania (MachadoVieira et al., 2004) . It causes hyperlocomotion, insomnia and increased sexual drive, representing face validity (Fiorino and Phillips, 1999) , it reproduces pathophysiological characteristics of the human condition (construct validity) (Frey et al., 2006d) , and responses to antimanic agents, such as antipsychotics and mood stabilizers (predictive validity) (Frey et al., 2006b,c) .
In this context, the present study aimed to investigate the effects of tamoxifen on locomotor behavior, on the activity of mitochondrial respiratory chain complexes and on CK activity in brains of rats subjected to an animal model of mania induced by D-AMPH.
Materials and methods

Animals
Adults male Wistar rats (250-300 g) were obtained from the Central Animal House of Universidade do Extremo Sul Catarinense. These animals were maintained on a 12-h light-dark cycle (lights on at 7:00 am), at a temperature of 23°C± 1°C and with free access to food and water. These conditions were maintained constant throughout the experiments. The rats were caged in groups of five in a 41× 34× 16 cm cage and divided randomly in 12 animals per group, totaling 96 animals. All behavioral data were conducted in a calm room by an experienced observer. The observer was in the room where experiments were performed and was blind to the animal condition.
All experimental procedures were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the Brazilian Society for Neuroscience and Behavior (SBNeC) recommendations for animal care, with the approval of the local Ethics Committee of Animals Use.
Drugs
Tamoxifen citrate (Salutas Pharma GmbH, Barleben, Ger.) and D-amphetamine (Sigma, St Louis, Mo.) were directly dissolved in saline (Sal) solution (NaCl 0.9%, w/v) and used in doses based on previous studies (TMX Einat et al., 2007; D-AMPH-Frey et al., 2006c) .
Reversal treatment
In the reversal model, we reproduced the treatment of acute manic episode according previously proposed (Frey et al., 2006c) . Rats received intraperitoneal (i.p.) injection of either D-AMPH (2 mg/kg) or Sal (1 mL/kg) once a day for a period of 14 days. From the 8th to the 14th day (treatment for 7 days), D-AMPH and Sal treated animals also received Sal (1 mL/kg i.p.-twice a day) or TMX (1 mg/kg i.p.-twice a day), totaling four experimental groups of 12 animals per group: Sal + Sal, Sal+ TMX, D-AMPH + Sal and D-AMPH + TMX. No behavioral assessment was performed between days 1-14. On the 15th day of treatment, the animals received a single injection of D-AMPH or Sal and locomotor activity was assessed using the open-field test 2 h after the injection, since pharmacokinetics studies have shown that half life of D-AMPH in the body is 60 min (Honecker and Coper, 1975) . The rats were killed by decapitation immediately after the open-field test and prefrontal cortex, hippocampus, striatum and amygdala were manually dissected on ice, rapidly frozen on dry ice and stored at −70°C until assayed (See Scheme 1).
Prevention treatment
This protocol was designed to mimic the prevention phase of BD treatment, as previously proposed (Frey et al., 2006c) . Rats received either Sal (1 mL/kg i.p.-twice a day) or TMX (1 mg/kg i.p.-twice a day) for a period of 14 days. From the 8th to the 14th day (treatment for 7 days), TMX and Sal treated animals also received Sal (1 mL/kg i.p.-once a day) or D-AMPH (2 mg/kg-once a day), totaling four experimental groups of 12 animals per group: Sal + Sal, TMX+ Sal, Sal + D-AMPH and TMX + D-AMPH. No behavioral assessment was performed between days 1 and 14. On the 15th day of treatment, the animals received a single injection of D-AMPH or Sal and locomotor activity was assessed using the open-field test 2 h after the injection. The rats were killed by decapitation immediately after the open-field test and prefrontal cortex, hippocampus, striatum and amygdala were manually dissected on ice, rapidly frozen on dry ice and stored at −70°C until assayed (See Scheme 2). Scheme 1. Treatment regime in reversal protocol.
Scheme 2. Treatment regime in prevention protocol.
Open-field test
On the 15th day of treatment, the animals received a single injection of D-AMPH or Sal, and 2 h after the injection locomotor activity was measured using the open-field test. The test was performed in a 40 × 60 cm open field surrounded by 50 cm high walls. The floor of the apparatus was constructed with varnished wood and divided into 9 equal rectangles by black lines. The animals were gently placed in one of the corner squares at the start of the test in order to explore the arena for 5 min. Crossings of the black lines and rearings (exploratory activity) were counted.
Activity of mitochondrial respiratory chain enzymes
Prefrontal cortex, hippocampus, striatum and amygdala were homogenized (1:10, w/v) in SETH buffer (250 mM sucrose, 2 mM EDTA, 10 mM Trizma base, 50 IU/ml heparin, pH 7.4). The homogenates were centrifuged at 800 g for 10 min and the supernatants were used for determining the activities of the mitochondrial respiratory chain enzymes (complexes I, II, III and IV). On the day of the assays, the samples were frozen and thawed thrice in hypotonic assay buffer to fully expose the enzymes to substrates and achieve maximal activities. NADH dehydrogenase (complex I) was evaluated by the method described by Cassina and Radi (1996) by the rate of NADH-dependent ferricyanide reduction at l = 420 nm. The activities of succinate-2,6-dichloroindophenol (DCIP)-oxidoreductase (complex II) and succinate: Cytochrome c oxidoreductase (complexes II-III) were determined by the method described by Fischer et al. (1985) . Complex II activity was measured by following the decrease in absorbance due to the reduction of 2,6-DCIP at l = 600 nm. Complex II-III activity was measured by cytochrome c reduction from succinate at l = 550 nm. The activity of cytochrome c oxidase (complex IV) was assayed according to the method described by Rustin et al. (1994) , measured by following the decrease in absorbance due to the oxidation of previously reduced cytochrome c at l = 550 nm. The activities of themitochondrial respiratory chain complexes were calculated as nmol/min mg protein.
Creatine kinase activity
Creatine kinase (CK) activity was assessed in brain homogenates pretreated with 0.625 mM lauryl maltoside. The reaction mixture consisted of 60 mM Tris-HCl, pH 7.5, containing 7 mM of phosphocreatine, 9 mM of MgSO 4 and approximately 0.4-1.2 μg of protein in a final volume of 100 μL. After 15 min of pre-incubation at 37°C, the reaction was started by the addition of 3.2 mmol of ADP plus 0.8 mmol of reduced glutathione. The reaction was stopped after 10 min by the addition of 1 μmol of p-hydroxymercuribenzoic acid. The creatine formed was estimated according to the colorimetric method of Hughes (1962) . The coloring was developed through the addition of 100 μL of 2%α-naphtol and 100 μL of 0.05% diacetyl in a final volume of 1 mL and read spectrophotometrically after 20 min at 540 nm. Results were expressed as mmol of creatine formed per min per mg protein.
Statistical analysis
Data were analyzed by two-way analysis of variance (ANOVA) followed by Tukey test when p values were significant (p b 0.05). All analyses were performed using the Statistical Package for the Social Science (SPSS) version 17.0 software.
Results
Reversal model
As illustrated in Fig. 1, D -AMPH administration increased crossings and rearings in saline-treated rats and this effect was reversed by TMX administration. TMX alone did not alter behavioral parameters in this protocol of treatment.
As shown in Fig. 2 , in the reversal treatment TMX administration in Sal-pretreated groups did not modify the complex viability ( Fig. 2A , C and D), except in hippocampus, where TMX decreased complex II activity (Fig. 2B) . The administration of D-AMPH resulted in a marked inhibition of complexes I ( Fig. 2A) , II (Fig. 2B) , III ( Fig. 2C) and IV ( Fig. 2D ) of mitochondrial respiratory chain in prefrontal cortex, hippocampus, striatum and amygdala. In the hippocampus and striatum the TMX administration partially reversed the decrease of complex II activity induced by D-AMPH (Fig. 2B) . On the other hand, the inhibition of complex IV was totally reversed by this drug in all brain regions analyzed (Fig. 2D) . Conversely, TMX did not modified the decreased activity of complex I ( Fig. 2A) and III (Fig. 2C) in the D-AMPH-treated group.
D-AMPH administration significantly inhibited CK activity in the rat's hippocampus and striatum, but not in the amygdala and prefrontal cortex (Fig. 3) . The administration of TMX reversed D-AMPH-induced inhibition of CK activity in hippocampus and striatum. Besides, in this protocol of treatment CK activity was significantly increased by the treatment with TMX in D-AMPH-groups in the prefrontal cortex of the rats. Results for mitochondrial respiratory chain complexes I, II, III and IV activity are shown in Fig. 5 . The treatment with Sal plus TMX decreased the activity of complex II in amygdala and complex IV in striatum. The administration of D-AMPH in the prevention protocol also resulted in a marked inhibition of complexes I (Fig. 5A) , II (Fig. 5B) , III (Fig. 5C ) and IV (Fig. 5D ) of mitochondrial respiratory chain in prefrontal cortex, hippocampus, striatum and amygdala. The inhibition of complexes I and III was totally prevented by TMX in all brain regions analyzed ( Fig. 5A and C, respectively) . Furthermore, TMX totally prevented D-AMPH-induced inhibition of complex II in prefrontal cortex and amygdala, but no effect of TMX on the mitochondrial alteration in the hippocampus and striatum was observed (Fig. 5B) . The administration of TMX significantly decreased the D-AMPH-induced complex IV inhibition in the prefrontal cortex, hippocampus and amygdale. In addition, TMX administration decreased partially the inhibition of complex IV activity in striatum (Fig. 5D) .
Prevention model
In the treatment of prevention, TMX alone decreased CK activity in amygdala, hippocampus and striatum, but not in the prefrontal cortex when compared to the control groups (Fig. 6) . Moreover, the administration of D-AMPH resulted in a marked inhibition of CK activity in the amygdala, hippocampus and striatum. The same was not observed in the prefrontal cortex. In the hippocampus and amygdala, the pretreatment with TMX potentiates the inhibition of CK activity induced by AMPH. In addition, CK activity inhibition induced by D-AMPH was not altered by the pretreatment with TMX in the striatum of the rats. In the prefrontal cortex, the pretreatment with TMX decreased CK activity in the D-AMPH-group.
Discussion
D-AMPH has profound effects on a wide range of physiological and behavioral processes: motor activity, ingestive behavior, sleep, attention, aggression, sexual behavior, learning and memory, classical conditioning and operant behavior (Seiden et al., 1993) . Psychostimulant-induced hyperactivity is the best established animal model of mania (MachadoVieira et al., 2004) . The hyperactivity induced by D-AMPH has been reported by several authors (Cappeliez and Moore, 1990; Einat et al., 2007; Szabo et al., 2009; Young et al., 2010) and this effect is mediated by an increased dopaminergic transmission in some brain regions, moreover, antipsychotic drugs used to treat acute mania are dopaminergic receptor antagonists (Meyer and Quenzer, 2005; Kapczinski and Quevedo, 2009 ). So, the data of the present study are in line with previous findings which showed consistent hyperlocomotor effects of D-AMPH in rats (Frey et al., 2006a,b,c,d; Mavrikaki et al., 2010; Valvassori et al., 2010) .
The reversion and prevention of D-AMPH-induced hyperlocomotion were seen after treatment with TMX, whose main action is to inhibit PKC, besides, the groups given TMX plus Sal did not differ from the control groups (Sal+ Sal), indicating that the effects of TMX could not be attributed to sedation. This finding confirms previous studies showing that TMX reduced the hyperactivity induced by D-AMPH in the openfield test (Einat et al., 2007) . Literature data also show that another inhibitor of PKC, Ro31-8220, when administered in the nucleus accumbens, attenuates the motor response produced by D-AMPH, an effect which was associated with the blocking of the dopamine release (Browman et al., 1998) . Additionally, Einat et al. (2007) showed that the administration of D-AMPH increased phosphorylation of GAP-43 protein-implicated in neuronal differentiation, plasticity and neurotransmitter release-and that pretreatment with TMX eliminates the effect of D-AMPH in this protein phosphorylation in parallel with behavioral changes, reinforcing the importance of modulation of PKC in the treatment of mania.
However, it is important to consider that TMX is also an estrogenic receptor modulator (with estrogenic and antiestrogenic effects), which could contribute to its behavioural effect. In this context, a study evaluated whether the antimanic effect of TMX is mediated through the PKC inhibitory and/or the antiestrogenic action(s) of the drug. TMX and chelerythrine (a PKC inhibitor) completely blocked the hyperlocomotion induced by D-AMPH. However, while the intermediate medroxyprogesterone (an antiestrogenic drug) dose partially reduced the D-AMPH-induced hyperlocomotion, lower and high doses produced no effect (Sabioni et al., 2008) , indicating a major role for PKC inhibition in the antimanic-like effect of TMX.
Our results also showed that D-AMPH administration resulted in an inhibition of complexes I, II, III and IV of mitochondrial respiratory chain in prefrontal cortex, hippocampus, striatum and amygdala, confirming previous studies that demonstrated a dysfunction in mitochondrial function during mania (Andreazza et al., 2010) .
Several evidences have shown that the activation of PKC enhances the release of dopamine, a neurotransmitter implicated in the manic syndrome (Robinson, 1991; Cowell et al., 2000; ) and that PKC inhibition reduces dopamine release induced by D-AMPH (Giambalvo, 1992; Kantor and Gnegy, 1998) . In this context, Przedborski et al. (1993) showed that the administration of levodopa (L-DOPA), the precursor of dopamine, was able to inhibit the activity of complex I in rat brains. This group also demonstrated that the incubation of mitochondria with dopamine and L-DOPA inhibited the activity of complex I in a time-dependent way, strengthening the link between dopaminergic hyperactivity and mitochondrial damage. Moreover, high levels of DA are related to increased cerebral oxidative stress and damage to mitochondrial function due to metabolism of oxidation of this monoamine (Kapczinski and Quevedo, 2009 ). In addition, it is important to emphasize that the increased activity of PKC induced by the administration of D-AMPH is related to an increased Ca 2 + influx (Yang and Kazanietz, 2003) . A large movement of positive charges of Ca 2 + into mitochondria increases the permeability of the mitochondrial membrane, decreasing its potential and exerting a depolarising effect (Quiroz et al., 2008) . These aspects are linked with the interruption of oxidative phosphorylation and production of ATP, with consequent release of cytochrome c and cell death by apoptosis (Rasola et al., 2010) . Together with our results, these studies suggest that inhibition of PKC, with consequent decrease in dopamine release is able to protect mitochondrial respiratory chain complexes viability against damage induced by D-AMPH. Here, we found that the inhibition of the mitochondrial respiratory chain complexes was prevented by TMX, however it varies depending on the protocol of treatment, brain region and complex activity evaluated, which may have occurred due to the longer treatment with SB in the reversal model when compared to the prevention protocol. Furthermore, regions of the central nervous system can respond distinctly (Sullivan et al., 2005) , and the activity of mitochondrial respiratory chain complexes was analyzed in different brain regions, which in part represent different cell types, indicating heterogeneity in terms of physiological and metabolic characteristics (Lai et al., 1977; Sims, 1991; Sonnewald et al., 1998) . Another interesting fact is that the treatment with Lithium and valproate-both PKC inhibitorsreverses the inhibition of mitochondrial respiratory chain complexes induced by D-AMPH (Valvassori et al., 2000) , results that are in agreement with those obtained in this study.
We also demonstrated that D-AMPH administration significantly inhibited CK activity in rat hippocampus and striatum. These results are consistent with a previous study of our research group (Streck et al., 2008) . In a postmortem study MacDonald et al. (2006) also demonstrated that levels of CK mRNA are decreased in BD patients, especially in the hippocampus. Together these studies suggest that the decrease in CK may have a role in BD.
Here we showed that TMX reverses the D-AMPH-induced CK activity inhibition. Conversely, the administration of lithium and valproatemood stabilizers that inhibit PKC-in D-AMPH-treated animals did not reverse the inhibition of the CK activity (Streck et al., 2008) . This discrepancy may be due to the fact that lithium and valproate have other mechanisms of action in addition to PKC inhibition, suggesting that specific inhibition of PKC by TMX may be a relation with CK modulation. Additionally, it is important to emphasize that TMX acts on estrogen receptor. Recently, studies have found that estrogen receptor agonists and antagonists stimulate energy metabolism, including CK activity (Somjen et al., 2008 (Somjen et al., , 2010 (Somjen et al., , 2011 . Together with our findings, these studies suggest that the modulation of CK by TMX can be via estrogen action.
On the other hand, in the prevention model, TMX decreased CK activity, both alone and co-administered with D-AMPH. According to our results, in a study that examined the effects of TMX in rats subjected to myocardial ischemia-reperfusion injury it was observed that the blood levels of CK were reduced after treatment with this drug (Ek et al., 2008) . Furthermore, CK activity in homogenate of hearts was inactivated by TMX about 20% at 10 mM of this drug (Miura et al., 2002) . This discrepancy may be explained due to the longer treatment with TMX in the prevention model compared to the reversal model, which may be causing adaptations and modulations in CK activity depending on the time of treatment with this drug.
The main limitation of this study is that TMX mechanism of action also involves estrogen receptor modulation, as previously mentioned. However, studies have indicated that this effects may contribute to its antimanic-like action (Sabioni et al., 2008) , moreover, it was demonstrated that addition of medroxyprogesterone in drug treatment improves mood in female patients with refractory mood disorder (Chouinard et al., 1987) , encouraging the use of antiestrogenic drugs as an another approach in the search for new mood stabilizing drugs.
Conclusion
In conclusion, the present study suggests that the mechanism of TMX action involves changes in the mitochondrial respiratory chain complexes and creatine kinase activities in parallel with behavioral changes, thus reinforcing the need for the study of inhibitors of PKC as a possible target for new medications to BD (Tables 1 and 2 ). 
